File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Cholangiocarcinoma in liver cirrhosis

TitleCholangiocarcinoma in liver cirrhosis
Authors
KeywordsCholangiocarcinoma
Hepatitis B
Liver cirrhosis
Median survival
Portal vein thrombosis
Issue Date2003
PublisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/JGH
Citation
Journal Of Gastroenterology And Hepatology, 2003, v. 18 n. 3, p. 337-341 How to Cite?
AbstractBackground and Aim: Hepatocellular carcinoma (HCC) is usually associated with chronic liver diseases and liver cirrhosis, while conversely, cholangiocarcinoma (CC) usually occurs in a non-cirrhotic liver. The purpose of the present study was to evaluate CC in liver cirrhosis. Methods: Between January 1998 and December 1999, 26 patients with CC were retrospectively reviewed. The occurrence of CC in chronic hepatitis B infection-related liver cirrhosis, portal vein thrombosis (PVT) and survival were analyzed. Results: Twenty-six patients with CC (19 with a non-cirrhotic liver and seven with chronic hepatitis B infection-related liver cirrhosis) were included in the present study. All cases of CC in the cirrhotic group were incidentally discovered during routine screening for HCC. The mean age (±SD) was 58.8±14 years in the cirrhotic group and 73.2±15.9 years (P=0.001) in the non-cirrhotic group. When compared to the cirrhotic group, the non-cirrhotic group had a higher median level of albumin (42 compared to 30 g/L, P=0.005), bilirubin (117.5 compared to 18 μmol/L, P=0.01), alkaline phosphatase (291.5 compared to 100 U/L, P=0.001) and gamma glutamyl transpeptidases (215.5 compared to 31 U/L, P=0.001). In contrast, the cirrhotic group had a higher median prothrombin time (PT) compared to the non-cirrhotic group (18.2 compared to 12s, P=0.05). In the non-cirrhotic group, only one patient (5.3%) showed evidence of PVT on a computerized tomography and Doppler ultrasound, while in the cirrhotic group six patients (85.7%) had PVT (P<0.001). The median survival period in the cirrhotic group was six months (range 2-24 months) compared to 16 months (range 6-41 months) in the non-cirrhotic group (P=0.036). Conclusion: CC in cirrhotic liver presented at a younger age and patients who developed CC were prone to PVT. The survival period was also shorter in comparison to that of non-cirrhotic liver patients. © 2003 Blackwell Publishing Asia Pty Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/77833
ISSN
2015 Impact Factor: 3.322
2015 SCImago Journal Rankings: 1.190
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorHui, CKen_HK
dc.contributor.authorYuen, MFen_HK
dc.contributor.authorTso, WKen_HK
dc.contributor.authorNg, IOLen_HK
dc.contributor.authorChan, AOOen_HK
dc.contributor.authorLai, CLen_HK
dc.date.accessioned2010-09-06T07:36:14Z-
dc.date.available2010-09-06T07:36:14Z-
dc.date.issued2003en_HK
dc.identifier.citationJournal Of Gastroenterology And Hepatology, 2003, v. 18 n. 3, p. 337-341en_HK
dc.identifier.issn0815-9319en_HK
dc.identifier.urihttp://hdl.handle.net/10722/77833-
dc.description.abstractBackground and Aim: Hepatocellular carcinoma (HCC) is usually associated with chronic liver diseases and liver cirrhosis, while conversely, cholangiocarcinoma (CC) usually occurs in a non-cirrhotic liver. The purpose of the present study was to evaluate CC in liver cirrhosis. Methods: Between January 1998 and December 1999, 26 patients with CC were retrospectively reviewed. The occurrence of CC in chronic hepatitis B infection-related liver cirrhosis, portal vein thrombosis (PVT) and survival were analyzed. Results: Twenty-six patients with CC (19 with a non-cirrhotic liver and seven with chronic hepatitis B infection-related liver cirrhosis) were included in the present study. All cases of CC in the cirrhotic group were incidentally discovered during routine screening for HCC. The mean age (±SD) was 58.8±14 years in the cirrhotic group and 73.2±15.9 years (P=0.001) in the non-cirrhotic group. When compared to the cirrhotic group, the non-cirrhotic group had a higher median level of albumin (42 compared to 30 g/L, P=0.005), bilirubin (117.5 compared to 18 μmol/L, P=0.01), alkaline phosphatase (291.5 compared to 100 U/L, P=0.001) and gamma glutamyl transpeptidases (215.5 compared to 31 U/L, P=0.001). In contrast, the cirrhotic group had a higher median prothrombin time (PT) compared to the non-cirrhotic group (18.2 compared to 12s, P=0.05). In the non-cirrhotic group, only one patient (5.3%) showed evidence of PVT on a computerized tomography and Doppler ultrasound, while in the cirrhotic group six patients (85.7%) had PVT (P<0.001). The median survival period in the cirrhotic group was six months (range 2-24 months) compared to 16 months (range 6-41 months) in the non-cirrhotic group (P=0.036). Conclusion: CC in cirrhotic liver presented at a younger age and patients who developed CC were prone to PVT. The survival period was also shorter in comparison to that of non-cirrhotic liver patients. © 2003 Blackwell Publishing Asia Pty Ltd.en_HK
dc.languageengen_HK
dc.publisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/JGHen_HK
dc.relation.ispartofJournal of Gastroenterology and Hepatologyen_HK
dc.subjectCholangiocarcinomaen_HK
dc.subjectHepatitis Ben_HK
dc.subjectLiver cirrhosisen_HK
dc.subjectMedian survivalen_HK
dc.subjectPortal vein thrombosisen_HK
dc.subject.meshAdulten_HK
dc.subject.meshAgeden_HK
dc.subject.meshAged, 80 and overen_HK
dc.subject.meshAntineoplastic Agents - administration & dosageen_HK
dc.subject.meshBile Duct Neoplasms - complications - mortality - therapyen_HK
dc.subject.meshBile Ducts, Intrahepatic - pathology - radiography - ultrasonographyen_HK
dc.subject.meshBiological Markers - blooden_HK
dc.subject.meshBiopsyen_HK
dc.subject.meshChemoembolization, Therapeuticen_HK
dc.subject.meshCholangiocarcinoma - complications - mortality - therapyen_HK
dc.subject.meshCholangiopancreatography, Endoscopic Retrogradeen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHong Kongen_HK
dc.subject.meshHumansen_HK
dc.subject.meshLiver Cirrhosis - complications - mortality - therapyen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshPlatelet Counten_HK
dc.subject.meshProthrombin Timeen_HK
dc.subject.meshSurvival Analysisen_HK
dc.subject.meshTomography, X-Ray Computeden_HK
dc.subject.meshTreatment Outcomeen_HK
dc.subject.meshUltrasonography, Doppleren_HK
dc.subject.meshalpha-Fetoproteins - metabolismen_HK
dc.titleCholangiocarcinoma in liver cirrhosisen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0815-9319&volume=18&issue=3&spage=337&epage=&date=2003&atitle=Cholangiocarcinoma+in+liver+cirrhosisen_HK
dc.identifier.emailYuen, MF:mfyuen@hkucc.hku.hken_HK
dc.identifier.emailNg, IOL:iolng@hkucc.hku.hken_HK
dc.identifier.emailLai, CL:hrmelcl@hku.hken_HK
dc.identifier.authorityYuen, MF=rp00479en_HK
dc.identifier.authorityNg, IOL=rp00335en_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1046/j.1440-1746.2003.02977.xen_HK
dc.identifier.pmid12603537-
dc.identifier.scopuseid_2-s2.0-0037366598en_HK
dc.identifier.hkuros79362en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0037366598&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume18en_HK
dc.identifier.issue3en_HK
dc.identifier.spage337en_HK
dc.identifier.epage341en_HK
dc.identifier.isiWOS:000181230600018-
dc.publisher.placeAustraliaen_HK
dc.identifier.scopusauthoridHui, CK=7202876933en_HK
dc.identifier.scopusauthoridYuen, MF=7102031955en_HK
dc.identifier.scopusauthoridTso, WK=7006905486en_HK
dc.identifier.scopusauthoridNg, IOL=7102753722en_HK
dc.identifier.scopusauthoridChan, AOO=7403167965en_HK
dc.identifier.scopusauthoridLai, CL=7403086396en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats